UnicoCell Biomed Co., Ltd. (TPE:6794)
Taiwan · Delayed Price · Currency is TWD 75.00
0.00 (0.00%)
Sep 8, 2026, 1:30 PM CST
UnicoCell Biomed Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 22.46 | 30.1 | 31.88 | 24.59 | 14.4 | 8.18 | |
Revenue Growth | -48.98% | -5.58% | 29.66% | 70.79% | 76.07% | 105.35% |
Cost of Revenue | 9.54 | 11.13 | 11.31 | 6.69 | 6.2 | 2.35 |
Gross Profit | 12.93 | 18.98 | 20.57 | 17.9 | 8.2 | 5.83 |
Selling, General & Admin | 41.14 | 41.6 | 34.85 | 31.4 | 25.4 | 23.3 |
Research & Development | 94.48 | 107.54 | 88.64 | 82.78 | 74.91 | 69.87 |
Operating Expenses | 135.82 | 149.26 | 123.49 | 114.18 | 100.31 | 93.17 |
Operating Income | -122.9 | -130.28 | -102.92 | -96.28 | -92.11 | -87.34 |
Interest Expense | -1.27 | -1.34 | -1.47 | -1.45 | -1.26 | -0.66 |
Interest & Investment Income | 11.47 | 10.1 | 7.54 | 5.79 | 0.84 | 0.08 |
Currency Exchange Gain (Loss) | 0.02 | 0.02 | 0.02 | 0.01 | 0.05 | - |
Other Non Operating Income (Expenses) | 7.95 | 7.33 | 5.13 | 3.04 | 1.18 | 1.54 |
EBT Excluding Unusual Items | -104.74 | -114.16 | -91.7 | -88.9 | -91.3 | -86.37 |
Gain (Loss) on Sale of Investments | 1.62 | -0.67 | -1.79 | - | 0.1 | - |
Gain (Loss) on Sale of Assets | - | - | 0.41 | 4.79 | - | - |
Other Unusual Items | - | - | - | - | 0.05 | - |
Pretax Income | -103.12 | -114.84 | -93.07 | -84.11 | -91.16 | -86.37 |
Net Income | -103.12 | -114.84 | -93.07 | -84.11 | -91.16 | -86.37 |
Net Income to Common | -103.12 | -114.84 | -93.07 | -84.11 | -91.16 | -86.37 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 63 | 61 | 57 | 54 | 41 | 38 |
Shares Outstanding (Diluted) | 63 | 61 | 57 | 54 | 41 | 38 |
Shares Change | 6.22% | 6.14% | 6.68% | 29.61% | 10.12% | 6.10% |
EPS (Basic) | -1.64 | -1.89 | -1.62 | -1.56 | -2.20 | -2.29 |
EPS (Diluted) | -1.65 | -1.89 | -1.62 | -1.56 | -2.20 | -2.29 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -81.33 | -96.81 | -66.84 | -81.35 | -78.05 | -85.34 |
Free Cash Flow Per Share | -1.29 | -1.59 | -1.17 | -1.51 | -1.88 | -2.27 |
Gross Margin | 57.54% | 63.04% | 64.52% | 72.78% | 56.93% | 71.32% |
Operating Margin | -547.16% | -432.77% | -322.83% | -391.56% | -639.78% | -1068.08% |
Profit Margin | -459.12% | -381.48% | -291.94% | -342.06% | -633.15% | -1056.30% |
Free Cash Flow Margin | -362.11% | -321.59% | -209.66% | -330.82% | -542.15% | -1043.70% |
EBITDA | -111.23 | -116.71 | -82.37 | -76.71 | -76.25 | -71.24 |
EBITDA Margin | - | - | -258.35% | - | - | - |
D&A For EBITDA | 11.67 | 13.57 | 20.56 | 19.57 | 15.86 | 16.1 |
EBIT | -122.9 | -130.28 | -102.92 | -96.28 | -92.11 | -87.34 |